Literature DB >> 22407885

Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease.

Kirsten Boonstra1, Karel J van Erpecum, Karin M J van Nieuwkerk, Joost P H Drenth, Alexander C Poen, Ben J M Witteman, Hans A R E Tuynman, Ulrich Beuers, Cyriel Y Ponsioen.   

Abstract

BACKGROUND: Primary sclerosing cholangitis (PSC) is strongly associated with inflammatory bowel disease (IBD). The aim of this study was to assess the IBD phenotype associated with PSC in a large well-phenotyped population-based PSC cohort using endoscopic and histopathologic criteria.
METHODS: PSC cases were identified and ascertained, fulfilling well-established criteria, in 39 hospitals in a geographically defined region of The Netherlands. IBD location was recorded according to the Montreal Classification. As this classification does not consider segmental inflammation, backwash ileitis, or rectal sparing, an additional subgroup analysis was performed in 80 cases and 80 age- and sex-matched IBD controls, reviewing all endoscopy and pathology reports filed between 2000 and 2010.
RESULTS: In all, 380 (66%) of a total of 579 PSC patients had coexistent IBD, mainly ulcerative colitis (UC) (75%). Overall, 207 (83%) of the PSC-UC patients had a pancolitis, 32 (13%) a left-sided colitis, and 9 (4%) a proctitis only. Seventy (95%) PSC-Crohn's disease (CD) patients had an (ileo)colitis and four (5%) ileitis only. In the subgroup analysis 53 (66%) PSC-UC patients were identified, 24 (30%) PSC-CD patients, and three (4%) PSC-IBD-U patients. Fifty (94%) PSC-UC patients had a pancolitis, compared with 32 (62%) matched UC patients (P < 0.001). Left-sided colitis was seen in 16 (31%) UC controls and in one PSC-UC patient (P < 0.001). Backwash ileitis and rectal sparing were rare findings (<10%) in the cohorts under study.
CONCLUSIONS: IBD in PSC patients represents a distinct phenotype in that pancolitis is observed in 94% of PSC-UC and colitis in 96% of PSC-CD patients. Backwash ileitis and rectal sparing were rare findings in the PSC-UC patients.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22407885     DOI: 10.1002/ibd.22938

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  58 in total

1.  Diagnosis, prognosis, and management of primary sclerosing cholangitis.

Authors:  Cyriel Ponsioen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-07

2.  The 2016 diagnostic criteria for primary sclerosing cholangitis.

Authors:  Takahiro Nakazawa; Kenji Notohara; Susumu Tazuma; Atsushi Tanaka; Hiroyuki Isayama; Toshio Tsuyuguchi; Toshiyuki Mori; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2016-12-05       Impact factor: 7.527

3.  Risk factors and clinical courses of concomitant primary sclerosing cholangitis and ulcerative colitis: a Korean multicenter study.

Authors:  Yong Eun Park; Jae Hee Cheon; Jae Jun Park; Yoon Jae Kim; Chang Hwan Choi; Yehyun Park; Soo Jung Park; Tae Il Kim; Won Ho Kim
Journal:  Int J Colorectal Dis       Date:  2018-07-09       Impact factor: 2.571

4.  Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases.

Authors:  Emily C Oxford; Deanna D Nguyen; Jenny Sauk; Joshua R Korzenik; Vijay Yajnik; Sonia Friedman; Ashwin N Ananthakrishnan
Journal:  Am J Gastroenterol       Date:  2013-02-19       Impact factor: 10.864

5.  Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon.

Authors:  Noa Krugliak Cleveland; David T Rubin; John Hart; Christopher R Weber; Katherine Meckel; Anthony L Tran; Arthur S Aelvoet; Isabella Pan; Alex Gonsalves; John Nick Gaetano; Kelli M Williams; Kristen Wroblewski; Bana Jabri; Joel Pekow
Journal:  Clin Gastroenterol Hepatol       Date:  2017-07-26       Impact factor: 11.382

6.  Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab.

Authors:  Ileana Duca; Patricia Ramírez de la Piscina; Silvia Estrada; Rosario Calderón; Katerina Spicakova; Leire Urtasun; Carlos Marra-López; Salvador Zabaleta; Raquel Bengoa; María Asunción Marcaide; Francisco García-Campos
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

7.  Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease.

Authors:  Ashwin N Ananthakrishnan; Andrew Cagan; Vivian S Gainer; Su-Chun Cheng; Tianxi Cai; Peter Szolovits; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao
Journal:  J Crohns Colitis       Date:  2014-02-19       Impact factor: 9.071

8.  Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls.

Authors:  Samaneh Ostadmohammadi; Masoumeh Azimirad; Hamidreza Houri; Kaveh Naseri; Ehsan Javanmard; Hamed Mirjalali; Abbas Yadegar; Amir Sadeghi; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Mol Biol Rep       Date:  2021-07-25       Impact factor: 2.316

9.  Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.

Authors:  B Christensen; D Micic; P R Gibson; A Yarur; E Bellaguarda; P Corsello; J N Gaetano; J Kinnucan; V L Rao; S Reddy; S Singh; J Pekow; D T Rubin
Journal:  Aliment Pharmacol Ther       Date:  2018-01-29       Impact factor: 8.171

10.  The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis.

Authors:  David F Schaeffer; Lay Lay Win; Sara Hafezi-Bakhtiari; Maria Cino; Gideon M Hirschfield; Hala El-Zimaity
Journal:  Dig Dis Sci       Date:  2013-05-14       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.